Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted the...
Saved in:
| Published in | Cancers Vol. 16; no. 4; p. 801 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
01.02.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers16040801 |
Cover
Loading…
| Abstract | Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. |
|---|---|
| AbstractList | Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy.Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. Cholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the various causes, risk factors, and molecular aspects of CCA in oncology. It explores current diagnostic methods and treatments, such as targeted therapies and immunotherapy. Additionally, it addresses emerging strategies like microbiota modulation and the use of natural compounds. This review paper provides a comprehensive understanding of CCA, offering insights into current and evolving approaches for effective interventions in oncological care. Simple SummaryCholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the various causes, risk factors, and molecular aspects of CCA in oncology. It explores current diagnostic methods and treatments, such as targeted therapies and immunotherapy. Additionally, it addresses emerging strategies like microbiota modulation and the use of natural compounds. This review paper provides a comprehensive understanding of CCA, offering insights into current and evolving approaches for effective interventions in oncological care.AbstractCholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting gene fusions and mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. Cholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the various causes, risk factors, and molecular aspects of CCA in oncology. It explores current diagnostic methods and treatments, such as targeted therapies and immunotherapy. Additionally, it addresses emerging strategies like microbiota modulation and the use of natural compounds. This review paper provides a comprehensive understanding of CCA, offering insights into current and evolving approaches for effective interventions in oncological care. Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy. |
| Audience | Academic |
| Author | Sampattavanich, Somponnat Tan, Jing Singh, Deepika Jusakul, Apinya Ko, Tun Kiat Guan, Peiyong Misra, Shagun Heng, Hong Lee Teh, Bin Tean Khosla, Divya Chan, Jason Yongsheng Hong, Jing Han Kapoor, Rakesh Klanrit, Poramate Kongpetch, Sarinya Nada, Ritambhra Kaewnarin, Khwanta Chu, Pek Lim Gupta, Rajesh Srinivasalu, Vijay Kumar |
| Author_xml | – sequence: 1 givenname: Divya surname: Khosla fullname: Khosla, Divya – sequence: 2 givenname: Shagun orcidid: 0000-0003-3196-5094 surname: Misra fullname: Misra, Shagun – sequence: 3 givenname: Pek Lim surname: Chu fullname: Chu, Pek Lim – sequence: 4 givenname: Peiyong orcidid: 0000-0001-9958-0137 surname: Guan fullname: Guan, Peiyong – sequence: 5 givenname: Ritambhra surname: Nada fullname: Nada, Ritambhra – sequence: 6 givenname: Rajesh surname: Gupta fullname: Gupta, Rajesh – sequence: 7 givenname: Khwanta orcidid: 0000-0003-0630-0357 surname: Kaewnarin fullname: Kaewnarin, Khwanta – sequence: 8 givenname: Tun Kiat surname: Ko fullname: Ko, Tun Kiat – sequence: 9 givenname: Hong Lee surname: Heng fullname: Heng, Hong Lee – sequence: 10 givenname: Vijay Kumar surname: Srinivasalu fullname: Srinivasalu, Vijay Kumar – sequence: 11 givenname: Rakesh surname: Kapoor fullname: Kapoor, Rakesh – sequence: 12 givenname: Deepika surname: Singh fullname: Singh, Deepika – sequence: 13 givenname: Poramate orcidid: 0000-0003-0209-3901 surname: Klanrit fullname: Klanrit, Poramate – sequence: 14 givenname: Somponnat orcidid: 0000-0001-7783-6103 surname: Sampattavanich fullname: Sampattavanich, Somponnat – sequence: 15 givenname: Jing surname: Tan fullname: Tan, Jing – sequence: 16 givenname: Sarinya surname: Kongpetch fullname: Kongpetch, Sarinya – sequence: 17 givenname: Apinya orcidid: 0000-0001-7652-7771 surname: Jusakul fullname: Jusakul, Apinya – sequence: 18 givenname: Bin Tean surname: Teh fullname: Teh, Bin Tean – sequence: 19 givenname: Jason Yongsheng orcidid: 0000-0002-4801-3703 surname: Chan fullname: Chan, Jason Yongsheng – sequence: 20 givenname: Jing Han orcidid: 0000-0002-2173-9192 surname: Hong fullname: Hong, Jing Han |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38398194$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1r3DAQxUVJaD6ac2_F0Esum4wsyZJ6W5Y0CaQklBR6M7I83lWwpY1kB_LfV0s-mi6p5iAx_N68Ee-A7PjgkZDPFE4Y03BqjbcYE62AgwL6geyXIMtZVWm-8-a9R45SuoN8GKOykh_JHlNMK6r5Pvm9WIXe-KUL1kTrfBjMt-InWvRjMW8fNg6pcL74EXq0U29icWPGVWhc6MPysTC-LW5XGM0ap9HZYr5ex2DsCtMnstuZPuHR831Ifn0_u11czK6uzy8X86uZ5YyNMwkGNPCOqRJ4wysBJWpJoZFcagAlKGUcSgFdpdqGCSEa2qBSbQdKW8XZITl-mpuN7ydMYz24ZLHPn8IwpbrUrOSMC1AZ_bqF3oUp-rzdhsqAFkr8pZamx9r5LozR2M3Qei4VByYr0Jk6eYfK1eLgbM6pc7n_j-DLs_nUDNjW6-gGEx_rlygycPoE2BhSiti9IhTqTd71Vt5ZIbYU1o1mdMHnXVz_X90fQtSsJg |
| CitedBy_id | crossref_primary_10_3390_cancers16244239 crossref_primary_10_1186_s12967_024_05857_6 crossref_primary_10_1097_MOT_0000000000001209 crossref_primary_10_3748_wjg_v31_i11_104170 crossref_primary_10_1080_14740338_2024_2380513 crossref_primary_10_1038_s41419_024_06839_8 crossref_primary_10_1038_s41598_024_81392_0 crossref_primary_10_1055_s_0044_1787959 crossref_primary_10_7759_cureus_66790 |
| Cites_doi | 10.1056/NEJMoa0908721 10.1097/01.SLA.0000065265.16728.C0 10.4254/wjh.v2.i12.419 10.3390/cancers15051569 10.1016/S0140-6736(22)02038-4 10.1016/j.ccell.2021.12.006 10.1002/bjs.10776 10.1001/jamaoncol.2019.0270 10.1038/ki.2008.129 10.1007/s12253-018-0491-8 10.1016/S1470-2045(20)30109-1 10.1016/j.bpg.2015.02.002 10.1097/01.sla.0000160701.38945.82 10.1038/ng.3375 10.1007/s10353-018-0529-x 10.1038/ng.2806 10.1016/j.bpg.2015.02.006 10.1093/annonc/mdt540 10.1136/oemed-2017-104603 10.1126/scitranslmed.aan6446 10.2217/fon-2020-0299 10.1055/s-0031-1272839 10.5858/arpa.2020-0725-OA 10.1016/j.asjsur.2015.07.002 10.1158/2159-8290.CD-17-0368 10.1136/gutjnl-2021-325178 10.1200/JCO.18.00050 10.7150/jca.13032 10.1038/bjc.2016.446 10.7326/0003-4819-158-6-201303190-00006 10.1016/j.surg.2020.04.068 10.1186/s12916-022-02426-w 10.1002/ijc.33013 10.1016/j.surg.2012.12.005 10.1016/S2468-1253(22)00043-7 10.1056/NEJMoa1500596 10.1093/annonc/mds652 10.1245/s10434-021-09871-6 10.1200/GO.20.00030 10.1053/j.gastro.2012.04.008 10.1038/ncomms6696 10.1007/s00534-009-0204-5 10.1200/JCO.2011.40.5381 10.4291/wjgp.v1.i1.12 10.1158/2159-8290.CD-16-1000 10.1080/13651820500373010 10.1016/j.ctrv.2011.05.003 10.1016/j.esmoop.2022.100505 10.1177/2631774521993065 10.1002/cncr.33356 10.1038/nrgastro.2017.75 10.1002/hep.26565 10.1002/jso.21376 10.1002/hep.26890 10.1016/j.aohep.2022.100737 10.1016/j.jamcollsurg.2007.07.002 10.1136/gutjnl-2012-303304 10.1001/jamaoncol.2020.0930 10.1002/bjs.10452 10.21873/anticanres.11404 10.1007/s11418-014-0851-y 10.1016/j.jhep.2020.03.008 10.1371/journal.pone.0163699 10.1007/s11605-019-04111-5 10.1002/hep.30852 10.3748/wjg.v16.i18.2235 10.1136/jitc-2020-000564 10.1007/s00268-015-2988-6 10.1097/PAS.0000000000000670 10.3390/diagnostics11060999 10.3389/fonc.2022.868034 10.3389/fgene.2020.00195 10.1093/annonc/mdz058 10.1016/j.jhep.2020.05.039 10.1093/annonc/mdh351 10.1016/j.radonc.2020.03.017 10.3892/or.2014.3059 10.1016/j.hpb.2021.06.423 10.1007/s10552-013-0167-3 10.1016/j.annonc.2020.02.011 10.1186/s12935-021-02081-w 10.1371/journal.pone.0277614 10.1631/jzus.B1900691 10.1126/scitranslmed.3006086 10.1016/S1072-7515(02)01287-5 10.1001/jamaoncol.2020.2814 10.1097/SLA.0b013e318176c4d3 10.1007/s00268-007-9001-y 10.1016/S1470-2045(23)00242-5 10.1146/annurev.immunol.26.021607.090331 10.1021/np100632g 10.3389/fcimb.2021.751795 10.1097/PAS.0000000000001118 10.3390/cancers13010039 10.1158/1078-0432.CCR-17-3725 10.1200/JCO.2012.41.5984 10.1056/NEJM199910283411807 10.1016/j.jhep.2019.09.007 10.1371/journal.pone.0171283 10.1093/annonc/mdz402 10.1021/np9003189 10.1126/science.aan6733 10.1007/s00268-021-06388-7 10.1111/jvh.12093 10.1371/journal.pone.0229292 10.3390/antiox12020376 10.1002/bjs.4815 10.1093/nar/gkr1095 10.1186/s13014-020-1459-x 10.1186/s13148-022-01413-5 10.21037/jgo.2018.08.18 10.1038/s41598-019-49860-0 10.1111/j.1478-3231.2009.01984.x 10.1039/c0mb00295j 10.1093/annonc/mdy119 10.1128/mBio.01343-17 10.1053/j.gastro.2013.08.058 10.1001/archsurg.2011.116 10.1111/hpb.12441 10.3390/cancers15072134 10.1371/journal.pone.0186643 10.1186/s13148-019-0634-0 10.1002/jhbp.1219 10.21037/cco.2016.10.09 10.3389/fphar.2019.00648 10.1056/NEJMc1713444 10.3390/diagnostics13020233 10.1002/hep.27050 10.21037/cco.2016.10.03 10.1007/s12094-021-02573-1 10.1038/bjc.2011.607 10.1200/JCO.2014.60.2219 10.1002/hep.32624 10.1111/cas.12300 10.1259/bjr.20190285 10.1038/s41467-022-30708-7 10.1002/ijc.33751 10.1038/ng.2273 10.1136/gutjnl-2023-330483 10.1002/hep.26092 10.1200/JCO.2023.41.4_suppl.LBA490 10.2147/DDDT.S80205 10.1016/j.ctarc.2021.100356 10.1136/jitc-2019-000367 10.1038/onc.2012.617 10.1111/j.1477-2574.2012.00489.x 10.1111/hpb.12450 10.1016/j.freeradbiomed.2013.07.034 10.1038/s41389-022-00415-5 10.1016/S1470-2045(20)30157-1 10.1186/s12876-017-0696-4 10.1245/s10434-018-6388-7 10.1056/NEJMra1706174 10.1056/NEJMra1506330 10.1097/01.sla.0000179678.13285.fa 10.1002/jhbp.314 10.1034/j.1600-6143.2002.20812.x 10.1016/S1470-2045(18)30915-X 10.7150/thno.56539 10.1093/annonc/mdi046 10.1007/s12072-021-10279-3 10.1093/annonc/mdw324 10.1016/S2468-1253(18)30234-6 10.1097/MOG.0000000000000162 10.1093/jn/130.2.391S 10.1038/ncomms5378 10.1016/j.mrfmmm.2010.06.003 10.1038/s41416-018-0138-2 10.1002/lt.20266 10.1016/S1470-2045(21)00027-9 10.1002/cncr.11699 10.1186/1471-2407-12-289 10.1093/annonc/mdv279 10.7314/APJCP.2014.15.17.7473 10.1016/j.ijrobp.2006.11.048 10.1002/hep.30863 10.1136/jitc-2020-001240 10.1186/s12885-017-3788-1 10.1007/s00066-018-1367-2 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI Q9U 7X8 |
| DOI | 10.3390/cancers16040801 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (ProQuest) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | A784037609 38398194 10_3390_cancers16040801 |
| Genre | Journal Article Review |
| GeographicLocations | Thailand Singapore India |
| GeographicLocations_xml | – name: Singapore – name: Thailand – name: India |
| GrantInformation_xml | – fundername: NCC Cancer Fund grantid: NCC Cancer Fund – fundername: AM/ACP-Designated Philanthropic Fund Grant Award grantid: 08/FY2023/EX/27-A65 – fundername: National Medical Research Council Open Fund - Individual Research Grant grantid: MOH-000144 and COVID19TUG21-0146 – fundername: National Medical Research Council Singapore Translational Research Investigator Award grantid: MOH-000248-00 – fundername: Singapore Ministry of Health's National Medical Research Council Research Transition Award grantid: TA21jun-0005 – fundername: Verdant Foundation grantid: Verdant Foundation – fundername: Singapore Therapeutics Development Review Pre-Pilot grantid: H23G1a0009 – fundername: 3rd A*STAR-AMED Joint Grant grantid: 236B9008 |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM PMFND 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c433t-70a0904f38204b46502e9710b7479008511340250f68db3555b1be88df089c843 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Fri Sep 05 12:12:57 EDT 2025 Fri Jul 25 11:44:35 EDT 2025 Tue Jun 17 22:17:05 EDT 2025 Tue Jun 10 21:12:47 EDT 2025 Thu Jan 02 22:35:57 EST 2025 Tue Jul 01 01:21:41 EDT 2025 Thu Apr 24 22:56:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | cholangiocarcinoma therapeutic approaches pathobiology |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c433t-70a0904f38204b46502e9710b7479008511340250f68db3555b1be88df089c843 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-2173-9192 0000-0002-4801-3703 0000-0003-3196-5094 0000-0001-7783-6103 0000-0001-7652-7771 0000-0001-9958-0137 0000-0003-0209-3901 0000-0003-0630-0357 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers16040801 |
| PMID | 38398194 |
| PQID | 2930839585 |
| PQPubID | 2032421 |
| ParticipantIDs | proquest_miscellaneous_2932434508 proquest_journals_2930839585 gale_infotracmisc_A784037609 gale_infotracacademiconefile_A784037609 pubmed_primary_38398194 crossref_primary_10_3390_cancers16040801 crossref_citationtrail_10_3390_cancers16040801 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-01 |
| PublicationDateYYYYMMDD | 2024-02-01 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2024 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | Lee (ref_137) 2019; 195 Nakanuma (ref_48) 2010; 2 Hasegawa (ref_109) 2007; 31 Khumkomkhet (ref_173) 2009; 72 Ebata (ref_98) 2018; 105 Zheng (ref_103) 2018; 119 Goyal (ref_66) 2017; 7 Ng (ref_36) 2017; 9 ref_11 Lazaridis (ref_20) 2016; 375 Hyder (ref_106) 2013; 153 Zhou (ref_113) 2017; 40 Lu (ref_150) 2022; 11 Rao (ref_181) 2022; 9 Wang (ref_130) 2022; 12 Deng (ref_177) 2022; 16 Zhang (ref_40) 2022; 13 ref_135 Montal (ref_6) 2020; 73 Koerkamp (ref_110) 2015; 26 Tournigand (ref_90) 2004; 15 Le (ref_161) 2017; 357 Ettrich (ref_65) 2019; 9 Feng (ref_164) 2020; 8 Mohamed (ref_45) 2016; 5 Weber (ref_127) 2015; 17 ref_125 Hong (ref_134) 2011; 146 Patil (ref_51) 2022; 146 ref_25 Song (ref_82) 2010; 17 Keir (ref_153) 2008; 26 Thongprasert (ref_152) 2005; 16 ref_21 Young (ref_14) 2014; 5 Smout (ref_15) 2011; 7 Shi (ref_118) 2020; 21 ref_123 Mahadevan (ref_136) 2015; 6 Dewulf (ref_185) 2013; 62 ref_27 Li (ref_180) 2022; 14 Sia (ref_18) 2013; 32 Elvevi (ref_10) 2022; 27 Coelen (ref_80) 2018; 3 Valle (ref_88) 2014; 25 Shroff (ref_94) 2023; 41 Chen (ref_166) 2020; 8 Nakachi (ref_101) 2023; 401 Debelle (ref_37) 2008; 74 Jia (ref_179) 2020; 71 Havnen (ref_22) 2004; 91 Kim (ref_162) 2020; 6 Lu (ref_44) 2020; 71 Heimbach (ref_86) 2004; 10 Oh (ref_163) 2020; 147 Sigel (ref_50) 2018; 42 Nakahashi (ref_112) 2020; 168 Murad (ref_133) 2012; 143 ref_74 Gores (ref_78) 1999; 341 Horgan (ref_97) 2012; 30 Decharchoochart (ref_171) 2014; 68 Liang (ref_111) 2021; 14 Li (ref_73) 2014; 60 Chen (ref_55) 2020; 11 Shroff (ref_91) 2019; 5 ref_147 ref_149 Fava (ref_4) 2010; 1 Nordenstedt (ref_24) 2012; 106 Corvera (ref_61) 2008; 206 Rizzo (ref_145) 2021; 27 Quinn (ref_79) 2018; 50 Sempoux (ref_46) 2011; 31 Jarnagin (ref_96) 2003; 98 Kamarajah (ref_121) 2021; 127 Arechederra (ref_69) 2022; 71 Vaquero (ref_146) 2018; 24 Kim (ref_93) 2019; 30 Ishihara (ref_95) 2016; 23 Liu (ref_72) 2020; 31 Bertuccio (ref_8) 2013; 24 Komaya (ref_114) 2017; 104 Maier (ref_187) 2017; 8 Macarulla (ref_143) 2020; 21 Xu (ref_174) 2014; 31 Roussel (ref_182) 2022; 46 Hemtasin (ref_172) 2011; 74 Hayashi (ref_52) 2016; 40 Zhang (ref_157) 2020; 73 Boonstra (ref_19) 2013; 58 Brandi (ref_30) 2013; 24 Farioli (ref_31) 2018; 75 Hemming (ref_77) 2003; 237 Zou (ref_39) 2014; 5 Dechakhamphu (ref_16) 2010; 691 Nassour (ref_120) 2018; 25 Kishimoto (ref_75) 2013; 104 Edeline (ref_99) 2019; 37 Gibson (ref_183) 2017; 14 ref_58 Poon (ref_38) 2013; 5 ref_57 Makawita (ref_141) 2020; 16 Ong (ref_5) 2012; 44 Zhou (ref_131) 2020; 147 ref_53 Deng (ref_155) 2021; 21 ref_178 Sebastian (ref_138) 2019; 19 Ritter (ref_184) 2017; 114 Wang (ref_108) 2013; 31 ref_59 Harding (ref_151) 2023; 24 Smits (ref_188) 2013; 145 Morizane (ref_89) 2019; 30 Nishio (ref_83) 2005; 7 Vigano (ref_156) 2019; 23 Lang (ref_176) 2009; 29 Sahai (ref_140) 2020; 21 Nakanuma (ref_47) 2015; 29 Dong (ref_43) 2022; 40 Guthrie (ref_122) 2015; 33 ref_67 Makridis (ref_23) 2022; 24 Otsuji (ref_81) 2015; 39 Hemming (ref_84) 2005; 241 Sudan (ref_132) 2002; 2 Jusakul (ref_12) 2015; 31 ref_64 ref_168 ref_62 Ren (ref_115) 2020; 15 Ralphs (ref_26) 2013; 20 Kongpetch (ref_56) 2020; 6 Ye (ref_154) 2009; 100 Clements (ref_9) 2020; 72 Thanan (ref_17) 2013; 65 Ong (ref_142) 2013; 45 ref_117 Yarchoan (ref_42) 2017; 377 Endo (ref_105) 2008; 248 Lamarca (ref_102) 2021; 22 Marinelli (ref_128) 2017; 37 Arai (ref_139) 2014; 59 Hahnvajanawong (ref_169) 2010; 16 Fisher (ref_107) 2012; 14 Weinberg (ref_159) 2019; 10 ref_32 Corcoran (ref_63) 2018; 379 Wasenang (ref_70) 2019; 11 Lendvai (ref_49) 2020; 26 Kwak (ref_175) 2015; 9 Lipshutz (ref_29) 2002; 195 Janeklang (ref_170) 2014; 15 Chen (ref_167) 2021; 149 Primrose (ref_100) 2019; 20 Le (ref_160) 2015; 372 Montes (ref_124) 2021; 23 Oh (ref_144) 2022; 7 Nakamura (ref_158) 2015; 47 Gibson (ref_186) 2000; 130 Valle (ref_1) 2016; 27 Yoo (ref_148) 2020; 8 Kongpetch (ref_13) 2015; 29 Lin (ref_41) 2021; 11 Liu (ref_71) 2018; 29 Mansour (ref_126) 2015; 17 Valle (ref_87) 2010; 362 Allal (ref_116) 2012; 38 Jung (ref_129) 2019; 92 Hughes (ref_119) 2007; 68 Jusakul (ref_2) 2017; 7 Sidorenko (ref_35) 2012; 40 Chaiteerakij (ref_28) 2013; 57 Deng (ref_7) 2023; 77 Fairweather (ref_3) 2016; 5 Han (ref_33) 2019; 10 Cosyns (ref_34) 2013; 158 Soares (ref_76) 2021; 28 Normanno (ref_54) 2022; 7 Tang (ref_60) 2023; 15 Rea (ref_85) 2005; 242 Shen (ref_68) 2019; 42 Kim (ref_104) 2017; 116 Klein (ref_165) 2020; 6 Ioka (ref_92) 2023; 30 |
| References_xml | – volume: 362 start-page: 1273 year: 2010 ident: ref_87 article-title: ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0908721 – volume: 237 start-page: 686 year: 2003 ident: ref_77 article-title: Preoperative portal vein embolization for extended hepatectomy publication-title: Ann. Surg. doi: 10.1097/01.SLA.0000065265.16728.C0 – volume: 2 start-page: 419 year: 2010 ident: ref_48 article-title: Pathological classification of intrahepatic cholangiocarcinoma based on a new concept publication-title: World J. Hepatol. doi: 10.4254/wjh.v2.i12.419 – ident: ref_147 doi: 10.3390/cancers15051569 – volume: 401 start-page: 195 year: 2023 ident: ref_101 article-title: Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(22)02038-4 – volume: 40 start-page: 70 year: 2022 ident: ref_43 article-title: Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma publication-title: Cancer Cell. doi: 10.1016/j.ccell.2021.12.006 – volume: 105 start-page: 192 year: 2018 ident: ref_98 article-title: Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer publication-title: Br. J. Surg. doi: 10.1002/bjs.10776 – volume: 5 start-page: 824 year: 2019 ident: ref_91 article-title: Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.0270 – volume: 74 start-page: 158 year: 2008 ident: ref_37 article-title: Aristolochic acid nephropathy: A worldwide problem publication-title: Kidney Int. doi: 10.1038/ki.2008.129 – volume: 26 start-page: 3 year: 2020 ident: ref_49 article-title: Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis publication-title: Pathol. Oncol. Res. doi: 10.1007/s12253-018-0491-8 – volume: 21 start-page: 671 year: 2020 ident: ref_140 article-title: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30109-1 – volume: 29 start-page: 233 year: 2015 ident: ref_13 article-title: Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways publication-title: Best Pract. Res. Clin. Gastroenterol. doi: 10.1016/j.bpg.2015.02.002 – volume: 241 start-page: 693 year: 2005 ident: ref_84 article-title: Surgical management of hilar cholangiocarcinoma publication-title: Ann. Surg. doi: 10.1097/01.sla.0000160701.38945.82 – volume: 47 start-page: 1003 year: 2015 ident: ref_158 article-title: Genomic spectra of biliary tract cancer publication-title: Nat. Genet. doi: 10.1038/ng.3375 – volume: 50 start-page: 93 year: 2018 ident: ref_79 article-title: Optimal perioperative care in peri-hilar cholangiocarcinoma resection publication-title: Eur. Surg. doi: 10.1007/s10353-018-0529-x – ident: ref_123 – volume: 45 start-page: 1474 year: 2013 ident: ref_142 article-title: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers publication-title: Nat. Genet. doi: 10.1038/ng.2806 – volume: 29 start-page: 277 year: 2015 ident: ref_47 article-title: Pathologic classification of cholangiocarcinoma: New concepts publication-title: Best Pract. Res. Clin. Gastroenterol. doi: 10.1016/j.bpg.2015.02.006 – volume: 25 start-page: 391 year: 2014 ident: ref_88 article-title: Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt540 – volume: 75 start-page: 191 year: 2018 ident: ref_31 article-title: Occupational exposure to asbestos and risk of cholangiocarcinoma: A population-based case-control study in four Nordic countries publication-title: Occup. Environ. Med. doi: 10.1136/oemed-2017-104603 – volume: 9 start-page: eaan6446 year: 2017 ident: ref_36 article-title: Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aan6446 – volume: 16 start-page: 2375 year: 2020 ident: ref_141 article-title: Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF 301 trial publication-title: Future Oncol. doi: 10.2217/fon-2020-0299 – volume: 31 start-page: 49 year: 2011 ident: ref_46 article-title: Intrahepatic cholangiocarcinoma: New insights in pathology publication-title: Semin. Liver Dis. doi: 10.1055/s-0031-1272839 – volume: 146 start-page: 220 year: 2022 ident: ref_51 article-title: HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/arpa.2020-0725-OA – volume: 40 start-page: 129 year: 2017 ident: ref_113 article-title: Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors publication-title: Asian J. Surg. doi: 10.1016/j.asjsur.2015.07.002 – volume: 7 start-page: 1116 year: 2017 ident: ref_2 article-title: Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0368 – volume: 71 start-page: 1141 year: 2022 ident: ref_69 article-title: Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures publication-title: Gut doi: 10.1136/gutjnl-2021-325178 – volume: 37 start-page: 658 year: 2019 ident: ref_99 article-title: Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.00050 – volume: 6 start-page: 1099 year: 2015 ident: ref_136 article-title: Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma publication-title: J. Cancer. doi: 10.7150/jca.13032 – volume: 116 start-page: 561 year: 2017 ident: ref_104 article-title: Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients publication-title: Br. J. Cancer doi: 10.1038/bjc.2016.446 – volume: 158 start-page: 469 year: 2013 ident: ref_34 article-title: The epidemiology, diagnosis, and management of aristolochic acid nephropathy: A narrative review publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-158-6-201303190-00006 – volume: 168 start-page: 617 year: 2020 ident: ref_112 article-title: How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma? publication-title: Surgery doi: 10.1016/j.surg.2020.04.068 – ident: ref_57 doi: 10.1186/s12916-022-02426-w – volume: 147 start-page: 2190 year: 2020 ident: ref_163 article-title: Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies publication-title: Int. J. Cancer. doi: 10.1002/ijc.33013 – volume: 153 start-page: 811 year: 2013 ident: ref_106 article-title: Recurrence after operative management of intrahepatic cholangiocarcinoma publication-title: Surgery doi: 10.1016/j.surg.2012.12.005 – volume: 7 start-page: 522 year: 2022 ident: ref_144 article-title: Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(22)00043-7 – volume: 372 start-page: 2509 year: 2015 ident: ref_160 article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1500596 – volume: 24 start-page: 1667 year: 2013 ident: ref_8 article-title: A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe publication-title: Ann. Oncol. doi: 10.1093/annonc/mds652 – volume: 28 start-page: 4158 year: 2021 ident: ref_76 article-title: The Landmark Series: Hilar Cholangiocarcinoma publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-021-09871-6 – volume: 6 start-page: 628 year: 2020 ident: ref_56 article-title: Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma publication-title: JCO Glob. Oncol. doi: 10.1200/GO.20.00030 – volume: 143 start-page: 88 year: 2012 ident: ref_133 article-title: Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.04.008 – volume: 5 start-page: 5696 year: 2014 ident: ref_39 article-title: Mutational landscape of intrahepatic cholangiocarcinoma publication-title: Nat. Commun. doi: 10.1038/ncomms6696 – volume: 17 start-page: 476 year: 2010 ident: ref_82 article-title: Surgical treatment of hilar cholangiocarcinoma in the new era: The Asan experience publication-title: J. Hepatobiliary Pancreat. Sci. doi: 10.1007/s00534-009-0204-5 – volume: 30 start-page: 1934 year: 2012 ident: ref_97 article-title: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.40.5381 – volume: 1 start-page: 12 year: 2010 ident: ref_4 article-title: Molecular mechanisms of cholangiocarcinoma publication-title: World J. Gastrointest. Pathophysiol. doi: 10.4291/wjgp.v1.i1.12 – volume: 7 start-page: 252 year: 2017 ident: ref_66 article-title: Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1000 – volume: 7 start-page: 259 year: 2005 ident: ref_83 article-title: Surgical management of hilar cholangiocarcinoma: The Nagoya experience publication-title: HPB doi: 10.1080/13651820500373010 – volume: 38 start-page: 111 year: 2012 ident: ref_116 article-title: Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2011.05.003 – volume: 7 start-page: 100505 year: 2022 ident: ref_54 article-title: Role of molecular genetics in the clinical management of cholangiocarcinoma publication-title: ESMO Open doi: 10.1016/j.esmoop.2022.100505 – volume: 14 start-page: 2631774521993065 year: 2021 ident: ref_111 article-title: Prognostic factors of resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis of high-quality studies publication-title: Ther. Adv. Gastrointest. Endosc. doi: 10.1177/2631774521993065 – volume: 127 start-page: 1266 year: 2021 ident: ref_121 article-title: Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis publication-title: Cancer doi: 10.1002/cncr.33356 – volume: 14 start-page: 491 year: 2017 ident: ref_183 article-title: Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2017.75 – volume: 58 start-page: 2045 year: 2013 ident: ref_19 article-title: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis publication-title: Hepatology doi: 10.1002/hep.26565 – volume: 100 start-page: 500 year: 2009 ident: ref_154 article-title: Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion publication-title: J. Surg. Oncol. doi: 10.1002/jso.21376 – volume: 59 start-page: 1427 year: 2014 ident: ref_139 article-title: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma publication-title: Hepatology doi: 10.1002/hep.26890 – volume: 27 start-page: 100737 year: 2022 ident: ref_10 article-title: Clinical treatment of cholangiocarcinoma: An updated comprehensive review publication-title: Ann. Hepatol. doi: 10.1016/j.aohep.2022.100737 – volume: 206 start-page: 57 year: 2008 ident: ref_61 article-title: 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer publication-title: J. Am. Coll. Surg. doi: 10.1016/j.jamcollsurg.2007.07.002 – volume: 62 start-page: 1112 year: 2013 ident: ref_185 article-title: Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women publication-title: Gut doi: 10.1136/gutjnl-2012-303304 – ident: ref_11 – volume: 6 start-page: 888 year: 2020 ident: ref_162 article-title: A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.0930 – volume: 104 start-page: 426 year: 2017 ident: ref_114 article-title: Nagoya Surgical Oncology Group. Recurrence after resection with curative intent for distal cholangiocarcinoma publication-title: Br. J. Surg. doi: 10.1002/bjs.10452 – volume: 37 start-page: 955 year: 2017 ident: ref_128 article-title: Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies publication-title: Anticanc. Res. doi: 10.21873/anticanres.11404 – volume: 68 start-page: 730 year: 2014 ident: ref_171 article-title: Cytotoxicity of compounds from the fruits of Derris indica against cholangiocarcinoma and HepG2 cell lines publication-title: J. Nat. Med. doi: 10.1007/s11418-014-0851-y – volume: 73 start-page: 315 year: 2020 ident: ref_6 article-title: Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.03.008 – ident: ref_74 doi: 10.1371/journal.pone.0163699 – volume: 23 start-page: 2216 year: 2019 ident: ref_156 article-title: Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery publication-title: J. Gastrointest. Surg. doi: 10.1007/s11605-019-04111-5 – volume: 71 start-page: 893 year: 2020 ident: ref_179 article-title: Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma publication-title: Hepatology doi: 10.1002/hep.30852 – volume: 16 start-page: 2235 year: 2010 ident: ref_169 article-title: Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v16.i18.2235 – volume: 8 start-page: e000564 year: 2020 ident: ref_148 article-title: Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer publication-title: J. Immunother. Cancer. doi: 10.1136/jitc-2020-000564 – volume: 39 start-page: 1494 year: 2015 ident: ref_81 article-title: Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection publication-title: World J. Surg. doi: 10.1007/s00268-015-2988-6 – volume: 40 start-page: 1021 year: 2016 ident: ref_52 article-title: Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000000670 – ident: ref_64 doi: 10.3390/diagnostics11060999 – volume: 12 start-page: 868034 year: 2022 ident: ref_130 article-title: Progress in Radiotherapy for Cholangiocarcinoma publication-title: Front. Oncol. doi: 10.3389/fonc.2022.868034 – volume: 11 start-page: 195 year: 2020 ident: ref_55 article-title: Genomic and Transcriptomic Landscape of Tumor Clonal Evolution in Cholangiocarcinoma publication-title: Front. Genet. doi: 10.3389/fgene.2020.00195 – volume: 30 start-page: 788 year: 2019 ident: ref_93 article-title: Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: A multicenter, open-label, randomized, phase III, noninferiority trial publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz058 – volume: 73 start-page: 1118 year: 2020 ident: ref_157 article-title: Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.05.039 – volume: 15 start-page: 1339 year: 2004 ident: ref_90 article-title: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study publication-title: Ann. Oncol. doi: 10.1093/annonc/mdh351 – volume: 147 start-page: 111 year: 2020 ident: ref_131 article-title: Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma publication-title: Radiother. Oncol. doi: 10.1016/j.radonc.2020.03.017 – volume: 31 start-page: 2063 year: 2014 ident: ref_174 article-title: Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo publication-title: Oncol. Rep. doi: 10.3892/or.2014.3059 – volume: 24 start-page: 267 year: 2022 ident: ref_23 article-title: The rate of cholangiocarcinoma in Caroli Disease a German multicenter study publication-title: HPB doi: 10.1016/j.hpb.2021.06.423 – volume: 24 start-page: 911 year: 2013 ident: ref_30 article-title: Asbestos: A hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis publication-title: Cancer Causes Control. doi: 10.1007/s10552-013-0167-3 – volume: 31 start-page: 745 year: 2020 ident: ref_72 article-title: Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.02.011 – volume: 21 start-page: 371 year: 2021 ident: ref_155 article-title: Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients publication-title: Cancer Cell Int. doi: 10.1186/s12935-021-02081-w – ident: ref_168 doi: 10.1371/journal.pone.0277614 – volume: 21 start-page: 549 year: 2020 ident: ref_118 article-title: Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: A meta-analysis publication-title: J. Zhejiang Univ. Sci. B doi: 10.1631/jzus.B1900691 – volume: 5 start-page: 197ra101 year: 2013 ident: ref_38 article-title: Genome-wide mutational signatures of aristolochic acid and its application as a screening tool publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3006086 – volume: 114 start-page: E367 year: 2017 ident: ref_184 article-title: Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals publication-title: Proc. Natl. Acad. Sci. USA – volume: 195 start-page: 713 year: 2002 ident: ref_29 article-title: Thorotrast-induced liver neoplasia: A collective review publication-title: J. Am. Coll. Surg. doi: 10.1016/S1072-7515(02)01287-5 – volume: 6 start-page: 1405 year: 2020 ident: ref_165 article-title: Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.2814 – volume: 9 start-page: 62 year: 2022 ident: ref_181 article-title: Alterations in the human oral microbiome in cholangiocarcinoma publication-title: Mil. Med Res. – volume: 248 start-page: 84 year: 2008 ident: ref_105 article-title: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection publication-title: Ann. Surg. doi: 10.1097/SLA.0b013e318176c4d3 – volume: 31 start-page: 1256 year: 2007 ident: ref_109 article-title: Surgical resection of hilar cholangiocarcinoma: Analysis of survival and postoperative complications publication-title: World J. Surg. doi: 10.1007/s00268-007-9001-y – volume: 24 start-page: 772 year: 2023 ident: ref_151 article-title: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(23)00242-5 – volume: 26 start-page: 677 year: 2008 ident: ref_153 article-title: PD-1 and its ligands in tolerance and immunity publication-title: Ann. Rev. Immunol. doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 74 start-page: 609 year: 2011 ident: ref_172 article-title: Cytotoxic pentacyclic and tetracyclic aromatic sesquiterpenes from Phomopsis archeri publication-title: J. Nat. Prod. doi: 10.1021/np100632g – ident: ref_178 doi: 10.3389/fcimb.2021.751795 – volume: 42 start-page: 1334 year: 2018 ident: ref_50 article-title: Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000001118 – ident: ref_67 doi: 10.3390/cancers13010039 – volume: 24 start-page: 4282 year: 2018 ident: ref_146 article-title: The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-3725 – volume: 31 start-page: 1188 year: 2013 ident: ref_108 article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy publication-title: J Clin. Oncol. doi: 10.1200/JCO.2012.41.5984 – volume: 341 start-page: 1368 year: 1999 ident: ref_78 article-title: Biliary tract cancers publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199910283411807 – volume: 72 start-page: 95 year: 2020 ident: ref_9 article-title: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis publication-title: J. Hepatol. doi: 10.1016/j.jhep.2019.09.007 – ident: ref_53 doi: 10.1371/journal.pone.0171283 – volume: 30 start-page: 1950 year: 2019 ident: ref_89 article-title: Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz402 – volume: 72 start-page: 1487 year: 2009 ident: ref_173 article-title: Antimalarial and cytotoxic depsidones from the fungus Chaetomium brasiliense publication-title: J. Nat. Prod. doi: 10.1021/np9003189 – ident: ref_32 – volume: 357 start-page: 409 year: 2017 ident: ref_161 article-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade publication-title: Science doi: 10.1126/science.aan6733 – volume: 46 start-page: 656 year: 2022 ident: ref_182 article-title: Influence of Probiotics Administration Before Liver Resection in Patients with Liver Disease: A Randomized Controlled Trial publication-title: World J. Surg. doi: 10.1007/s00268-021-06388-7 – volume: 20 start-page: 297 year: 2013 ident: ref_26 article-title: The role of the hepatitis viruses in cholangiocarcinoma publication-title: J. Viral Hepat. doi: 10.1111/jvh.12093 – ident: ref_117 doi: 10.1371/journal.pone.0229292 – ident: ref_149 doi: 10.3390/antiox12020376 – volume: 91 start-page: 1538 year: 2004 ident: ref_22 article-title: Bile duct cysts in adults publication-title: Br. J. Surg. doi: 10.1002/bjs.4815 – volume: 40 start-page: 2494 year: 2012 ident: ref_35 article-title: Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkr1095 – volume: 15 start-page: 15 year: 2020 ident: ref_115 article-title: A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma publication-title: Radiat. Oncol. doi: 10.1186/s13014-020-1459-x – volume: 15 start-page: 13 year: 2023 ident: ref_60 article-title: Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients publication-title: Clin. Epigenetics. doi: 10.1186/s13148-022-01413-5 – volume: 10 start-page: 652 year: 2019 ident: ref_159 article-title: Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets publication-title: J. Gastrointest. Oncol. doi: 10.21037/jgo.2018.08.18 – volume: 9 start-page: 13261 year: 2019 ident: ref_65 article-title: Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information publication-title: Sci. Rep. doi: 10.1038/s41598-019-49860-0 – volume: 29 start-page: 670 year: 2009 ident: ref_176 article-title: Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells publication-title: Liver Int. doi: 10.1111/j.1478-3231.2009.01984.x – volume: 7 start-page: 1367 year: 2011 ident: ref_15 article-title: Infection with the carcinogenic human liver fluke, Opisthorchis viverrini publication-title: Mol. Biosyst. doi: 10.1039/c0mb00295j – volume: 29 start-page: 1445 year: 2018 ident: ref_71 article-title: Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy119 – volume: 8 start-page: e01343-17 year: 2017 ident: ref_187 article-title: Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome publication-title: mBio doi: 10.1128/mBio.01343-17 – volume: 145 start-page: 946 year: 2013 ident: ref_188 article-title: Therapeutic potential of fecal microbiota transplantation publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.08.058 – volume: 146 start-page: 683 year: 2011 ident: ref_134 article-title: Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: A 24-year experience in a single center publication-title: Arch. Surg. doi: 10.1001/archsurg.2011.116 – volume: 17 start-page: 669 year: 2015 ident: ref_127 article-title: Intrahepatic Cholangiocarcinoma: Expert consensus statement publication-title: HPB doi: 10.1111/hpb.12441 – ident: ref_58 doi: 10.3390/cancers15072134 – ident: ref_21 doi: 10.1371/journal.pone.0186643 – volume: 11 start-page: 39 year: 2019 ident: ref_70 article-title: Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases publication-title: Clin. Epigenetics doi: 10.1186/s13148-019-0634-0 – volume: 30 start-page: 102 year: 2023 ident: ref_92 article-title: Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA) publication-title: J. Hepatobiliary Pancreat. Sci. doi: 10.1002/jhbp.1219 – volume: 5 start-page: 61 year: 2016 ident: ref_45 article-title: Biliary tract cancers: Epidemiology, molecular pathogenesis and genetic risk associations publication-title: Chin. Clin. Oncol. doi: 10.21037/cco.2016.10.09 – volume: 10 start-page: 648 year: 2019 ident: ref_33 article-title: Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.00648 – volume: 377 start-page: 2500 year: 2017 ident: ref_42 article-title: Tumor Mutational Burden and Response Rate to PD-1 Inhibition publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1713444 – ident: ref_62 doi: 10.3390/diagnostics13020233 – volume: 60 start-page: 896 year: 2014 ident: ref_73 article-title: Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis publication-title: Hepatology doi: 10.1002/hep.27050 – volume: 5 start-page: 63 year: 2016 ident: ref_3 article-title: Surgical management of biliary tract cancers publication-title: Chin. Clin. Oncol. doi: 10.21037/cco.2016.10.03 – volume: 23 start-page: 988 year: 2021 ident: ref_124 article-title: SEOM clinical guidelines for pancreatic and biliary tract cancer (2020) publication-title: Clin. Transl. Oncol. doi: 10.1007/s12094-021-02573-1 – volume: 106 start-page: 1011 year: 2012 ident: ref_24 article-title: Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.607 – volume: 33 start-page: 2617 year: 2015 ident: ref_122 article-title: SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.60.2219 – volume: 77 start-page: 411 year: 2023 ident: ref_7 article-title: Proteogenomic characterization of cholangiocarcinoma publication-title: Hepatology doi: 10.1002/hep.32624 – volume: 104 start-page: 1626 year: 2013 ident: ref_75 article-title: Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer publication-title: Cancer Sci. doi: 10.1111/cas.12300 – volume: 92 start-page: 20190285 year: 2019 ident: ref_129 article-title: Mapping of local recurrence after pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma: Implications for adjuvant radiotherapy publication-title: Br. J. Radiol. doi: 10.1259/bjr.20190285 – volume: 13 start-page: 3061 year: 2022 ident: ref_40 article-title: The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers publication-title: Nat. Commun. doi: 10.1038/s41467-022-30708-7 – volume: 149 start-page: 1944 year: 2021 ident: ref_167 article-title: Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial publication-title: Int. J. Cancer doi: 10.1002/ijc.33751 – volume: 44 start-page: 690 year: 2012 ident: ref_5 article-title: Exome sequencing of liver fluke-associated cholangiocarcinoma publication-title: Nat. Genet. doi: 10.1038/ng.2273 – ident: ref_59 doi: 10.1136/gutjnl-2023-330483 – volume: 42 start-page: 549 year: 2019 ident: ref_68 article-title: Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer publication-title: Oncol. Rep. – volume: 57 start-page: 648 year: 2013 ident: ref_28 article-title: Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk publication-title: Hepatology doi: 10.1002/hep.26092 – volume: 41 start-page: LBA490 year: 2023 ident: ref_94 article-title: SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary trac t cancers publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2023.41.4_suppl.LBA490 – volume: 9 start-page: 2201 year: 2015 ident: ref_175 article-title: Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma publication-title: Drug Des. Devel. Ther. doi: 10.2147/DDDT.S80205 – volume: 27 start-page: 100356 year: 2021 ident: ref_145 article-title: IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? publication-title: Cancer Treat. Res. Commun. doi: 10.1016/j.ctarc.2021.100356 – volume: 8 start-page: e000367 year: 2020 ident: ref_164 article-title: Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase II study publication-title: J. Immunother. Cancer. doi: 10.1136/jitc-2019-000367 – volume: 32 start-page: 4861 year: 2013 ident: ref_18 article-title: Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for molecular therapies publication-title: Oncogene doi: 10.1038/onc.2012.617 – volume: 14 start-page: 514 year: 2012 ident: ref_107 article-title: Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: A multi-institution analysis publication-title: HPB doi: 10.1111/j.1477-2574.2012.00489.x – volume: 17 start-page: 691 year: 2015 ident: ref_126 article-title: Hilar cholangiocarcinoma: Expert consensus statement publication-title: HPB doi: 10.1111/hpb.12450 – volume: 65 start-page: 1464 year: 2013 ident: ref_17 article-title: Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2013.07.034 – volume: 11 start-page: 39 year: 2022 ident: ref_150 article-title: NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis publication-title: Oncogenesis doi: 10.1038/s41389-022-00415-5 – volume: 21 start-page: 796 year: 2020 ident: ref_143 article-title: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30157-1 – ident: ref_27 doi: 10.1186/s12876-017-0696-4 – volume: 25 start-page: 1193 year: 2018 ident: ref_120 article-title: Adjuvant Therapy Is Associated with Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-018-6388-7 – volume: 379 start-page: 1754 year: 2018 ident: ref_63 article-title: Application of Cell-free DNA Analysis to Cancer Treatment publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1706174 – ident: ref_125 – volume: 375 start-page: 1161 year: 2016 ident: ref_20 article-title: Primary Sclerosing Cholangitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1506330 – volume: 242 start-page: 451 year: 2005 ident: ref_85 article-title: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma publication-title: Ann. Surg. doi: 10.1097/01.sla.0000179678.13285.fa – volume: 23 start-page: 149 year: 2016 ident: ref_95 article-title: Biliary tract cancer registry in Japan from 2008 to 2013 publication-title: J Hepatobiliary Pancreat. Sci doi: 10.1002/jhbp.314 – volume: 2 start-page: 774 year: 2002 ident: ref_132 article-title: Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma publication-title: Am. J. Transplant. doi: 10.1034/j.1600-6143.2002.20812.x – volume: 20 start-page: 663 year: 2019 ident: ref_100 article-title: Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30915-X – volume: 11 start-page: 4585 year: 2021 ident: ref_41 article-title: Mutational spectrum and precision oncology for biliary tract carcinoma publication-title: Theranostics doi: 10.7150/thno.56539 – volume: 16 start-page: 279 year: 2005 ident: ref_152 article-title: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma publication-title: Ann. Oncol. doi: 10.1093/annonc/mdi046 – volume: 16 start-page: 99 year: 2022 ident: ref_177 article-title: Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer publication-title: Hepatol. Int. doi: 10.1007/s12072-021-10279-3 – volume: 27 start-page: 28 year: 2016 ident: ref_1 article-title: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw324 – volume: 3 start-page: 681 year: 2018 ident: ref_80 article-title: Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: A multicentre, randomised controlled trial publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(18)30234-6 – volume: 19 start-page: 66 year: 2019 ident: ref_138 article-title: Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma publication-title: Clin. Transl. Radiat. Oncol. – volume: 31 start-page: 258 year: 2015 ident: ref_12 article-title: Genetics of Opisthorchis viverrini-related cholangiocarcinoma publication-title: Curr. Opin. Gastroenterol. doi: 10.1097/MOG.0000000000000162 – volume: 130 start-page: 391S year: 2000 ident: ref_186 article-title: Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use publication-title: J. Nutr. doi: 10.1093/jn/130.2.391S – volume: 14 start-page: 2962 year: 2022 ident: ref_180 article-title: Characteristics of bile microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and pancreatic cancer publication-title: Am. J. Transl. Res. – volume: 5 start-page: 4378 year: 2014 ident: ref_14 article-title: The Opisthorchis viverrini genome provides insights into life in the bile duct publication-title: Nat. Commun. doi: 10.1038/ncomms5378 – volume: 691 start-page: 9 year: 2010 ident: ref_16 article-title: Accumulation of miscoding etheno-DNA adducts and highly expressed DNA repair during liver fluke-induced cholangiocarcinogenesis in hamsters publication-title: Mutat. Res. doi: 10.1016/j.mrfmmm.2010.06.003 – volume: 119 start-page: 291 year: 2018 ident: ref_103 article-title: A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin publication-title: Br. J. Cancer doi: 10.1038/s41416-018-0138-2 – volume: 10 start-page: S65 year: 2004 ident: ref_86 article-title: Transplantation for hilar cholangiocarcinoma publication-title: Liver Transpl. doi: 10.1002/lt.20266 – volume: 22 start-page: 690 year: 2021 ident: ref_102 article-title: Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00027-9 – volume: 98 start-page: 1689 year: 2003 ident: ref_96 article-title: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies publication-title: Cancer doi: 10.1002/cncr.11699 – ident: ref_25 doi: 10.1186/1471-2407-12-289 – volume: 26 start-page: 1930 year: 2015 ident: ref_110 article-title: Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv279 – volume: 15 start-page: 7473 year: 2014 ident: ref_170 article-title: In vitro and in vivo antitumor activity of tiliacorinine in human cholangiocarcinoma publication-title: Asian Pac. J. Cancer Prev. doi: 10.7314/APJCP.2014.15.17.7473 – volume: 68 start-page: 178 year: 2007 ident: ref_119 article-title: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2006.11.048 – volume: 71 start-page: 929 year: 2020 ident: ref_44 article-title: The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers publication-title: Hepatology doi: 10.1002/hep.30863 – volume: 8 start-page: e001240 year: 2020 ident: ref_166 article-title: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: A single-arm, open-label, phase II trial publication-title: J. Immunother. Cancer. doi: 10.1136/jitc-2020-001240 – ident: ref_135 doi: 10.1186/s12885-017-3788-1 – volume: 195 start-page: 93 year: 2019 ident: ref_137 article-title: Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: A meta-analysis and systematic review publication-title: Strahlenther. Onkol. doi: 10.1007/s00066-018-1367-2 |
| SSID | ssj0000331767 |
| Score | 2.4143982 |
| SecondaryResourceType | review_article |
| Snippet | Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses... Cholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This review covers the... Simple SummaryCholangiocarcinoma (CCA) manifests as a complex interplay of genetic and environmental factors, necessitating personalized approaches. This... |
| SourceID | proquest gale pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 801 |
| SubjectTerms | Aristolochic acid Asbestos Bile ducts Biopsy Carcinogens Chemotherapy Cholangiocarcinoma Cisplatin Cysts Development and progression Diagnosis Drug approval Drug development Dysbacteriosis Environmental factors Epigenetic inheritance Epigenetics Fibroblast growth factor receptor 2 Gallbladder diseases Gemcitabine Gene mutations Genetic transcription Genomes Health aspects Hepatitis B Hepatitis C Immunosuppressive agents Immunotherapy Infections Inflammation Intestinal microflora Kinases Liver Liver cirrhosis Malignancy Medical research Medicine, Experimental Microbiota Microbiota (Symbiotic organisms) Mutation Nitric oxide Oncology Oxaliplatin Parasites Post-transcription Precision medicine Radiation therapy Radiotherapy Risk factors Type 2 diabetes Viral infections |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS-wwEB50hYMv4uWo9UYEwfPSY3eTtokvsooiwoqIwr6VJk1F0K5u1__vl2264oK-NpNQMpmZbyaTGaIjbqUC8NWhia0IRWp1CD8kCsvCJN0yj3g6DWUPbpPrR3EzjIc-4Fb7tMpWJ04VdTEyLkZ-ArMEtKCAbs_e3kPXNcrdrvoWGou0BBUs4w4tnV_e3t3PoiwRh31M0qamD4d_f2LcZo7rboLTK30rmNYczSvlOag5NTlXq7TisSLrN8xdowVbrdOfgb8N36DhhXNMq6dn2KMxPo1e81MGHAg7wvrN3X7Nnis2aFvgsjvgvbbuEsurgj18Pb9ifV9e3NZ_6fHq8uHiOvSdEkIjOJ-EaZRHKhIlhz0XWgB19awCdtBwFlSDqrhwaKdMZKEBMWLd1VbKooykMlLwTepUo8puE5MaEg0fJE4KrJ0L0OSltkWamsSWqgzof7thmfFlxF03i5cM7oTb4WxuhwP6N5vw1lTQ-Jn02HEgc7KFNU3unwjgz1yVqqyfwh11WTwqoL1vlJAJ83245WHmZbLOvk5QQIezYTfT5ZlVdvQxpekJLoBaA9pqeD_7afjyCvhJ7Py--C4t9wB8mszuPepMxh92H8Blog_86fwEX4jsPA priority: 102 providerName: ProQuest |
| Title | Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38398194 https://www.proquest.com/docview/2930839585 https://www.proquest.com/docview/2932434508 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3bS-NAFMYPbgXZl2W9rXFrmQVBX-KmmekksyBSxQsLFRELfQuZyUQETde2wu5_v9_kUmlR8DWZDMmZMzm_L5k5h2if21gBfLVvelb4IrLahw4J_DwzspunAY_KT9mDa3k1FL9HvdFrOaDagNM3pZ2rJzWcPB79ff53ggl_7BQnJPtP4-wzmXYlHDJ2e7lWEZakc_FBzfrla5kjVJYVZcMgCn0plahS_bzVx0KUWn5XLxFoGYkuvtKXGiFZvxrzdVqxxQatDeqf5Js0OnMPVdw_IExNcGj8lP5iwEOEF9avfvlP2UPBBk1lXHYDDGzSMbG0yNjd664s1q-zjtvpFg0vzu_Orvy6gIJvBOczPwrSQAUi5wjzQgvAWGgVkEJDQ6gKtrhwEJTLONMgj57uahvHWR7EysSCb1OrGBd2h1isMdEhTXoyQ9-pQJs01zaLIiNtrnKPjhqDJabOLu6KXDwmUBnOwsmShT06nF_wp0qs8X7TAzcCiXMC9GnSeucA7swlr0r6EVSqW9yjPGovtMRUMYunmzFMGk9LwDvAUAXZ5NGP-Wl3pVt-VtjxS9kmFFwAZj36Vo39_KYh8RWwSux-_IG-0-cQbFQt_m5TazZ5sXtgm5nu0Orp-fXNbYc-XY66ndKD_wOzRvbm |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFD70Amtfxu7z1q0adGwvXh1Lsa3BGFkvpJeEMlLIm2fJcim0ThYnjP2p_cZ9iuWUBtq3vloXjM45-r4jHZ1DtMNNIkF8la_bRvgiNsqHHxL4Ra6jVpEFPJ4fZff6UfdcHA_bwxX617yFsWGVzZ4436jzkbZn5LuAJbAFCXb7ffzbt1Wj7O1qU0KjVosT8_cPXLbq29E-5PsxDA8PBntd31UV8LXgfOrHQRbIQBQc2CeUAEMJjQTOKhBrWTMQLiwzKKIkV4DjtmopkyR5ESRSJ4Jj3lVaB82QsKL1Hwf9s5-LU52AA4-juM4hxLkMdrUV3qRqRbCWxJWeaeBvGQSWqO0c4g6f0GPHTVmnVqantGLKZ_So527fn9NwzzrC5cUl8G-CT6Pr7CsD7wRusU4dS1Cxy5L1mpK77Az8ssnzxLIyZ4Ob516s49KZm-oFnT_IGr6ktXJUmtfEEoUdBD5PO8oxdybQJyuUyeNYR6aQhUdfmgVLtUtbbqtnXKVwX-wKp0sr7NHnxYBxnbHj7q6frARSa8uYU2fuSQL-zGbFSjsx3F8bNSQ92rrVEzaobzc3MkzdHlClNxrr0YdFsx1p49pKM5rN-4SCC7Bkj17Vsl_8NMdg8DXx5v7Jt2mjO-idpqdH_ZO3tBmCdNVR5Vu0Np3MzDuQpql67zSV0a-HNo7_zkAlMA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTpp4QcAGBAYYaQheQtPYTWwkhMq2amNrVaFN6luIHQdNgnQ0nRD_Gn8dnxun0yrB217jH4p8d_6-s893RHvcSgXiq0PTtyIUqdUh_JAoLAuT9Mo84unyKHs0To7Oxedpf7pBf9q3MC6sst0Tlxt1MTPujLwLWAJbUGC33dKHRUwOhh8vf4augpS7aW3LaTQqcmJ__4L7Vn84PoCsX8fx8PBs_yj0FQZCIzhfhGmURyoSJQcOCi3AVmKrgLkaJFs1bIQLxxLKRBYa0NzXPW2lLMpIKiMFx7x3aDMFKsoObX46HE--rE54Ig5sTtImnxDnKuoaJ8h53UtgOdKXoWmhcB0Q1mjuEu6G9-me56ls0CjWA9qw1UPaGvmb-G2a7junuPp2ASyc49PsR_6egYMCw9igiSuo2UXFRm35XTYB12xzPrG8KtjZ9dMvNvCpzW29Q-e3soaPqFPNKvuEmNTYTeD_9JMCc-cCffJS2yJNTWJLVQb0rl2wzPgU5q6SxvcMroxb4WxthQN6uxpw2WTv-HfXN04CmbNrzGly_zwBf-YyZGWDFK6wiyBSAe3e6Al7NDebWxlmfj-os2vtDejVqtmNdDFulZ1dLfvEggsw5oAeN7Jf_TTHYHA38fT_k7-kLRhFdno8PnlGd2PwrybAfJc6i_mVfQ7-tNAvvKIy-nrbtvEXb_4pXA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cholangiocarcinoma%3A+Recent+Advances+in+Molecular+Pathobiology+and+Therapeutic+Approaches&rft.jtitle=Cancers&rft.au=Khosla%2C+Divya&rft.au=Misra%2C+Shagun&rft.au=Chu%2C+Pek+Lim&rft.au=Guan%2C+Peiyong&rft.date=2024-02-01&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=16&rft.issue=4&rft.spage=801&rft_id=info:doi/10.3390%2Fcancers16040801&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_cancers16040801 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |